Metabolic Dysfunction-Associated Steatotic Liver Disease : Global Epidemiology, Patient-Reported Outcomes, and Economic Impact - 15/05/26

Doi : 10.1016/j.cld.2026.01.001

James M. Paik, PhD ^a,^b, Linda Henry, PhD ^a, Khalid AlNaamani, MD ^a,^c, Ariana Nader, BS ^a, Maria Stepanova, PhD ^a,^b, Mei-Hsuan Lee, PhD ^a,^d, Ming-Lung Yu, MD, PhD ^a,^e,^f, Zobair M. Younossi, MD, MPH ^a,^b,^g,^⁎

^a The Global NASH/MASH Council (GNC), Washington DC, USA

^b The Global Center for Liver Outcomes and Policy Research Georgetown University School of Medicine, Washington, DC, USA

^c Division of Gastroenterology and Hepatology, Department of Medicine, The Medical City for Military and Security Services, Muscat, Oman

^d National Yang Ming Chiao Tung University, Taipei, Taiwan

^e Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Center of Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan

^f Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwan

^g Center for Outcomes Research in Liver Disease, Washington, DC, USA

^∗ Corresponding author. The Global NASH/MASH Council, Center for Outcomes Research in Liver Diseases, 2411 I Street, Washington DC 20037. The Global NASH/MASH Council Center for Outcomes Research in Liver Diseases 2411 I Street Washington DC 20037

Résumé

In 2023, new terminology [metabolic dysfunction associated steatotic liver disease (MASLD)] was introduced adressing the shortfalls (stigma/underreporting of alcohol) of nonalcoholic fatty liver disease (NAFLD). MASLD falls within a SLD spectrum dependent upon cardio-metabolic risk factors (CMRFs) and alcohol consumption [MASLD (< 20 g females/30 g males), MetALD (<50g females/<60 g males), and ALD (≥ 50g females/ ≥ 60 g males). HRQL, economic burden, fibrosis, cirrhosis, cancer, and mortality are inversely related with alcohol and presence of multiple CMRFs. Adult prevalence rates of MASLD, Met-ALD and ALD are 30%+, 2.2%-10%, and 1%-3%, respectively. Increased awareness of SLD and decreasing alcohol consumption interventions are needed.

Le texte complet de cet article est disponible en PDF.

Keywords : Prevalence, Incidence, Outcomes, CVD, CKD, Economic, Humanistic, SDOH

Plan

Export

Vol 30 - N° 2

P. 241-269 - mai 2026 Retour au numéro

Article précédent

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies
Zobair M. Younossi

| Article suivant

Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases : Diabetes, Prediabetes, and Obesity
Leonidas Diamantopoulos, Markos Kalligeros, Scott D. Isaacs, Didac Mauricio

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Metabolic Dysfunction-Associated Steatotic Liver Disease : Global Epidemiology, Patient-Reported Outcomes, and Economic Impact - 15/05/26

Résumé

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL